Tebentafusp in combination with durvalumab and/or tremelimumab in patients with metastatic cutaneous melanoma: a phase 1 study

BACKGROUND: Immune checkpoint inhibitors have significantly improved outcomes in first line cutaneous melanoma. However, there is a high unmet need for patients who progress on these therapies and combination therapies are being explored to improve outcomes. Tebentafusp is a first-in-class gp100×CD3...

Descripción completa

Detalles Bibliográficos
Autores principales: Hamid, Omid, Hassel, Jessica C, Shoushtari, Alexander N, Meier, Friedegund, Bauer, Todd M, Salama, April K S, Kirkwood, John M, Ascierto, Paolo A, Lorigan, Paul C, Mauch, Cornelia, Orloff, Marlana, Evans, Thomas R Jeffry, Holland, Chris, Edukulla, Ramakrishna, Abedin, Shaad E, Middleton, Mark R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10254987/
https://www.ncbi.nlm.nih.gov/pubmed/37286303
http://dx.doi.org/10.1136/jitc-2023-006747

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10254987/
https://www.ncbi.nlm.nih.gov/pubmed/37286303
http://dx.doi.org/10.1136/jitc-2023-006747

Ejemplares similares